Treatment of acute hepatitis C: The success of monotherapy with (pegylated) interferon α

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 860-865

  Wiegand, Johannes ^a   Deterding, Katja ^b   Cornberg, Markus ^b   Wedemeyer, Heiner ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antiviral therapy; Hepatology; Liver disease

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANTIVIRAL THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG RESPONSE; EDITORIAL; HEPATITIS C; HUMAN; INFECTION CONTROL; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SELECTION; SUICIDE; TREATMENT DURATION; TREATMENT PLANNING; VIRUS INFECTIVITY; VIRUS LOAD;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; INTERFERON-ALPHA;

EID: 54549108005     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn346     Document Type: Editorial

References (59)

1. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36 (Suppl. 1): S30-34.
2. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-905.
3. Santantonio T, Sinisi E, Guastadisegni A et al. Natural course of acute hepatitis C: A long-term prospective study. Dig Liver Dis 2003; 35: 104-13.
4. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001; 33: 321-7.
5. Mondelli MU, Cerino A, Cividini A. Acute hepatitis C: Diagnosis and management. J Hepatol 2005; 42 (Suppl. 1): S108-14.
6. Heller T, Rehermann B. Acute hepatitis C: A multifaceted disease. Semin Liver Dis 2005; 25: 7-17.
7. Wang CC, Krantz E, Klarquist J et al. Acute hepatitis C in a contemporary US cohort: Modes of acquisition and factors influencing viral clearance. J Infect Dis 2007; 196: 1474-82.
8. Brouard C, Pradat P, Delarocque-Astagneau E et al. Epidemiological characteristics and medical follow-up of 61 patients with acute hepatitis C identified through the hepatitis C surveillance system in France. Epidemiol Infect 2008; 136: 988-96.
9. Robert Koch Institut. Virushepatitis B, C und D im Jahr 2006. Epid Bull 2007; 49: 457-68.
10. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-62.
11. Roy K, Hay G, Andragetti R et al. Monitoring hepatitis C Virus infection among injecting drug users in the European Union: A review of the literature. Epidemiol Infect 2002; 129: 577-85.
12. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18: 352-8.
13. Deterding K, Wiegand J, Gruner N et al. Medical procedures as a risk factor for HCV infection in developed countries: Do we neglect a significant problem in medical care? J Hepatol 2008; 48: 1019-26.
14. Santantonio T, Medda E, Ferrari C et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 2006; 43: 1154-9.
15. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: A global review. J Hepatol 2006; 45 607-16.
16. Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis - United States 2005. MMWR Surveill Summ 2007; 56: 1-24.
17. Martinez-Bauer E, Forns X, Armelles M et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol 2008; 48: 20-7.
18. Lurie Y, Landau DA, Blendis L et al. Acute hepatitis C in Israel: a predominantly iatrogenic disease? J Gastroenterol Hepatol 2007; 22: 158-64.
19. Kubitschke A, Bader C, Tillmann HL et al. Injuries from needles contaminated with hepatitis C virus: How high is the risk of seroconversion for medical personnel really? Internist (Berl) 2007; 48: 1165-72.
20. Mele A, Tosti ME, Marzolini A et al. Prevention of hepatitis C in Italy: Lessons from surveillance of type-specific acute viral hepatitis. SEIEVA collaborating Group. J Viral Hepat 2000; 7: 30-5.
21. Tosti ME, Solinas S, Prati D et al. An estimate of the current risk of transmitting blood-borne infections through blood transfusion in Italy. Br J Haematol 2002; 117: 215-9.
22. Kondili LA, Chionne P, Costantino A et al. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 2002; 50: 693-6.
23. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
24. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
25. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
26. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon α-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 20 04; 40: 993-9.
27. Zeuzem S, Buti M, Ferenci P et al. Efficacy of 24 weeks treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.
28. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kDa)/ribavirin therapy. Hepatology 2006; 43: 954-60.
29. Sanchez-Tapias JM, Diago M, Escartin P et al. Peginterferon-α2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-60.
30. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-α-2a plus ribavirin. Gastroenterology 2006; 130 1086-97.
31. Dalgard O, Bjoro K, Ring-Larsen H et al. Pegylated interferon α and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008; 47: 35-42.
32. Dalgard O, Bjoro K, Hellum KB et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology 2004; 40: 1260-5.
33. von Wagner M, Huber M, Berg T et al. Peginterferon-α-2a (40 kDa) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-7.
34. Mangia A, Santoro R, Minerva N et al. Peginterferon α-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.
35. Shiffman ML, Ghany MG, Morgan TR et al. Impact of reducing peginterferon α-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132: 103-12.
36. Vogel W, Graziadei I, Umlauft F et al. High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C: A pilot study. Dig Dis Sci 1996; 41 (Suppl.): 81S-5S.
37. Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon α2b. N Engl J Med 2001; 345: 1452-7.
38. Delwaide J, Bourgeois N, Gerard C et al. Treatment of acute hepatitis C with interferon α-2b: Early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther 2004; 20: 15-22.
39. Nomura H, Sou S, Tanimoto H et al. Short-term interferon-α therapy for acute hepatitis C: A randomized controlled trial. Hepatology 2004; 39: 1213-9.
40. Wiegand J, Buggisch P, Boecher W et al. Early monotherapy with pegylated interferon α-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. Hepatology 2006; 43: 250-6.
41. De Rosa FG, Bargiacchi O, Audagnotto S et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon α-2b treatment for acute hepatitis C. J Antimicrob Chemother 2006; 57: 360-3.
42. Calleri G, Cariti G, Gaiottino F et al. A short course of pegylated interferon-α in acute HCV hepatitis. J Viral Hepat 2007; 14: 116-21.
43. Santantonio T, Fasano M, Sinisi E et al. Efficacy of a 24-week course of PEG-interferon α-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005; 42: 329-33.
44. Licata A, Di Bona D, Schepis F et al. When and how to treat acute hepatitis C? J Hepatol 2003; 39: 1056-62.
45. Wiegand J, Jäckel E, Cornberg M et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004; 40: 98-107.
46. Corey KE, Ross AS, Wurcel A et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol 2006; 4: 1278-82.
47. Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125: 80-8.
48. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: A systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41.
49. Kamal SM, Ismail A, Graham CS et al. Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004; 39: 1721-31.
50. Manns MP, Meyer S, Wedemeyer H. The German network of excellence for viral hepatitis (Hep-Net). Hepatology 2003; 38: 543-4.
51. Kamal SM, Fouly AE, Kamel RR et al. Peginterferon α-2b therapy in acute hepatitis C: Impact of onset of therapy on sustained virologic response. Gastroenterology 2006; 130: 632-8.
52. Wedemeyer H, Cornberg M, Wiegand J et al. Treatment of acute hepatitis C-how to explain the differences? Gastroenterology 2006; 131: 682-3.
53. Hofer H, Watkins-Riedel T, Janata O et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37 60-4.
54. Kamal SM, Moustafa KN, Chen J et al. Duration of peginterferon therapy in acute hepatitis C: A randomized trial. Hepatology 2006; 43: 923-31.
55. Wedemeyer H, Cornberg M, Wiegand J et al. Treatment duration in acute hepatitis C: The issue is not solved yet. Hepatology 2006; 44: 1051-2.
56. De Rosa FG, Bargiacchi O, Audagnotto S et al. Twelve-week treatment of acute hepatitis C virus with pegylated interferon-α-2b in injection drug users. Clin Infect Dis 2007; 45: 583-8.
57. Broers B, Helbling B, Francois A et al. Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005; 42: 323-8.
58. Nguyen OK, Dore GJ, Kaldor JM et al. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study. Int J Drug Policy 2007; 18: 447-51.
59. Grebely J, Genoway K, Khara M et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18: 437-43.